蓝帆医疗股份有限公司 2018 年年度报告全文 1 蓝帆医疗股份有限公司 BLUE SAIL MEDICAL CO.,LTD. （山东省淄博市齐鲁化学工业区清田路 21 号） 二〇一八年年度报告 股票代码：002382 二〇一九年四月 蓝帆医疗股份有限公司 2018 年年度报告全文 金转增股本。 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 公司负责人刘文静、主管会计工作负责人孙传志及会计机构负责人(会计主 管人员)白雪莲声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司已在本年度报告中详细描述了公司面临的风险，敬请投资者予以关注， | --- | |-----------------------------------------------------------------------------------------| | | | | | 详见本年度报告 " 经营情况讨论与分析 " 等章节中关于公司面临风险的描述。 | ...

BLUE SAIL MEDICAL CO.,LTD. （山东省淄博市齐鲁化学工业区清田路 21 号） 二〇一八年第三季度报告 蓝帆医疗股份有限公司 2018 年第三季度报告全文 蓝帆医疗股份有限公司 （未经审计） 股票代码：002382 二〇一八年十月 1 蓝帆医疗股份有限公司 2018 年第三季度报告全文 第一节 重要提示 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 14,379,354,128.08 | | 1,837,037,124.62 | 682.75% | | 归属于上市公司股东的净资产 | 7,446,026,028.72 | | 1,426,156,427.31 | 422.10% | | （元） | | | | | | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | | | 增减 | | 年同期增减 | | 营业收入（元） | 82 ...

蓝帆医疗股份有限公司 2018 年半年度报告全文 蓝帆医疗股份有限公司 BLUE SAIL MEDICAL CO.,LTD. （山东省淄博市齐鲁化学工业区清田路 21 号） 二〇一八年半年度报告 （未经审计） 股票代码：002382 二〇一八年八月 1 蓝帆医疗股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人刘文静、主管会计工作负责人孙传志及会计机构负责人(会计主管人员)白雪 莲声明：保证本半年度报告中财务报告的真实、准确、完整。 公司发行股份及支付现金购买资产并募集配套资金暨关联交易之标的资产过户已于 2018 年 5 月 14 日完成，基于公司未来发展战略的考虑，公司存在对董事会、监事会和高级 管理人员进行调整的需要，王相武先生、吴强先生、韩邦友先生于 2018 年 8 月 24 日辞去董 事职务，韩邦友先生、张永臣先生、曹元和先生和张木存先生于 2018 年 8 月 24 日辞去高管 职务，前述人员的辞职当日生效，不再对 ...

Financial Performance - The company's operating revenue for Q1 2018 was ¥384,864,033.82, a decrease of 4.39% compared to ¥402,521,260.12 in the same period last year[7] - Net profit attributable to shareholders was ¥58,400,299.33, representing a 12.11% increase from ¥52,091,827.29 year-on-year[7] - Basic earnings per share rose to ¥0.12, a 9.09% increase compared to ¥0.11 in the same period last year[7] - The company reported a significant increase in revenue for Q1 2018, with a year-over-year growth of 25%[29] - The total comprehensive income for Q1 2018 was CNY 57,316,228.43, compared to CNY 51,953,095.92 in the same quarter last year, marking an increase of 10.5%[54] - The net profit for Q1 2018 reached CNY 58,074,261.54, representing an increase of 11.5% from CNY 52,078,743.04 in Q1 2017[53] - The company reported a decrease in sales expenses, which were CNY 12,819,469.37 in Q1 2018, down from CNY 17,922,096.00 in Q1 2017, reflecting a reduction of 28.4%[53] Cash Flow and Assets - The net cash flow from operating activities increased by 41.88% to ¥60,172,360.97, up from ¥42,409,359.62 in the previous year[7] - Cash and cash equivalents decreased by 49.36% to ¥119,711,925.53, primarily due to increased investments in the "6 billion pieces/year health protection (new gloves) project" and environmental equipment upgrades[15] - The ending balance of cash and cash equivalents was CNY 114,991,925.53, a decrease from CNY 282,972,355.87 in the previous period[61] - The company reported a significant increase in cash outflows for operating activities, totaling CNY 266,981,521.81, compared to CNY 127,868,755.57 in the previous period[64] - The cash inflow from sales of goods and services was CNY 117,444,218.26, reflecting a stable revenue stream[63] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,781[11] - The largest shareholder, Zibo Blue Sail Investment Co., Ltd., held 29.72% of the shares, amounting to 146,900,000 shares[11] - The net assets attributable to shareholders decreased by 1.47% to ¥1,405,200,259.17 from ¥1,426,156,427.31 at the end of the previous year[7] Strategic Initiatives and Acquisitions - The company is undergoing a significant asset restructuring, with stock trading suspended since July 24, 2017, due to planned asset acquisition[20] - The company plans to acquire a total of 62.61% of CBCH II shares from 17 counterparties for a total transaction price of 589,527.34 million CNY[22] - The acquisition has received preliminary approval from the China Securities Regulatory Commission (CSRC) and is pending final approval[24] - The company is actively pursuing market expansion and strategic acquisitions to enhance its business portfolio[22] - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2018[30] Research and Development - Research and development expenses increased by 18% in Q1 2018, reflecting the company's commitment to innovation and new technology[30] Regulatory Compliance - The company has committed to maintaining strict compliance with regulatory requirements, ensuring all acquisitions and expansions are aligned with industry standards[31] - The company is required to respond to the CSRC's feedback on the asset purchase application within 30 working days[23] Future Outlook - The company provided a positive outlook for the upcoming quarters, projecting a revenue growth of 20% for the full year 2018[30] - New product launches are expected to contribute an additional 10% to revenue in Q2 2018, with two new medical devices set to be released[30] - The company has set a performance guidance of achieving a net profit margin of 15% for the fiscal year 2018[30]

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=Section%201%20Important%20Notice,%20Table%20of%20Contents,%20and%20Definitions) This section contains important disclaimers, the report's table of contents, and key definitions [Important Notice](index=2&type=section&id=Important%20Notice) The board, supervisory board, and senior management guarantee the accuracy and completeness of this annual report, proposing a cash dividend of 2.00 yuan per 10 shares - Company management ensures the truthfulness, accuracy, and completeness of the 2017 annual report and assumes legal responsibility[3](index=3&type=chunk) - The 2017 profit distribution plan proposes a cash dividend of **2.00 yuan per 10 shares** (tax inclusive) based on 494,355,000 shares, with no bonus shares or capital reserve conversions[4](index=4&type=chunk) [Company Profile and Key Financial Indicators](index=5&type=section&id=Section%202%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section provides an overview of the company and its key financial performance metrics for the reporting period [Company Information and Key Financial Indicators](index=5&type=section&id=Company%20Information%20and%20Key%20Financial%20Indicators) Lanfei Medical Co., Ltd. reported 2017 revenue of 1.576 billion yuan, up 22.28%, and net profit attributable to shareholders of 201 million yuan, up 10.93% Key Accounting Data and Financial Indicators for 2017 | Indicator | 2017 | 2016 | Year-on-Year Change | | :--- | :--- | :--- | :--- | | **Operating Revenue (yuan)** | 1,575,945,309.43 | 1,288,770,719.80 | 22.28% | | **Net Profit Attributable to Shareholders (yuan)** | 200,864,341.90 | 181,069,380.03 | 10.93% | | **Net Profit Attributable to Shareholders Excluding Non-recurring Gains/Losses (yuan)** | 199,887,711.25 | 160,824,059.80 | 24.29% | | **Net Cash Flow from Operating Activities (yuan)** | 227,567,253.64 | 163,926,593.84 | 38.82% | | **Basic Earnings Per Share (yuan/share)** | 0.41 | 0.37 | 10.81% | | **Weighted Average Return on Net Assets** | 14.87% | 14.66% | 0.21% | | **Total Assets (yuan)** | 1,837,037,124.62 | 1,587,014,886.30 | 15.75% | | **Net Assets Attributable to Shareholders (yuan)** | 1,426,156,427.31 | 1,298,896,635.77 | 9.80% | Key Quarterly Financial Indicators for 2017 (Unit: yuan) | Indicator | Q1 | Q2 | Q3 | Q4 | | :--- | :--- | :--- | :--- | :--- | | **Operating Revenue** | 402,521,260.12 | 378,254,459.81 | 377,603,157.13 | 417,566,432.37 | | **Net Profit Attributable to Shareholders** | 52,091,827.29 | 51,281,427.21 | 55,866,058.46 | 41,625,028.94 | | **Net Cash Flow from Operating Activities** | 42,409,359.62 | 122,090,150.30 | 76,077,824.27 | -13,010,080.55 | - During the reporting period, the company's total non-recurring gains and losses amounted to **976,600 yuan**, primarily from government subsidies, investment income, and disposal of non-current assets[21](index=21&type=chunk)[22](index=22&type=chunk) [Company Business Overview](index=9&type=section&id=Section%203%20Company%20Business%20Overview) This section outlines the company's primary business, core products, and competitive advantages [Company Business and Core Competencies](index=9&type=section&id=Company%20Business%20and%20Core%20Competencies) The company's main business is health protective glove production, holding the global top market share in PVC gloves, while expanding into nitrile gloves and high-value medical consumables - The company's main business is the production and sale of health protective gloves (primarily PVC gloves), establishing it as a global leader in this segment with supply chain advantages[25](index=25&type=chunk)[26](index=26&type=chunk) - The first phase of the company's '6 billion units/year Health Protective (New Type Gloves) Project' (2 billion units/year nitrile gloves) commenced production in June 2017, with the second phase under construction, aiming to diversify product categories and meet growing demand for nitrile gloves[26](index=26&type=chunk)[27](index=27&type=chunk) - The company is entering the high-value medical consumables sector, such as coronary stents, through a major asset restructuring, aiming for industrial upgrading and new growth drivers[31](index=31&type=chunk) - Core competencies include: - **Market**: Established a global marketing system through its US subsidiary Omni and domestic branches, achieving the **world's largest market share** in similar products - **Products**: Added nitrile glove categories and leverages channel advantages for multi-product portfolio sales - **Production**: Achieves cost reduction and efficiency gains through cost control and standardized operations - **Technology**: Independently developed intelligent equipment, holding **over 50 patents** - **Supply Chain**: The only company in the industry with integrated upstream raw material supply (plasticizers, PVC paste resin)[29](index=29&type=chunk)[30](index=30&type=chunk)[31](index=31&type=chunk)[32](index=32&type=chunk) [Management Discussion and Analysis](index=12&type=section&id=Section%204%20Management%20Discussion%20and%20Analysis) This section provides a detailed analysis of the company's operational performance and financial condition during the reporting period [Operating Overview](index=12&type=section&id=I.%20Overview) In 2017, the company implemented an 'A+X' strategy, strengthening its core health protective glove business while expanding into high-value medical consumables, achieving a net profit of 201 million yuan - The company fully implemented an **A+X strategy**, encompassing a business layout of 'low-value consumables (health protective gloves) + high-value consumables (cardiac stents, etc.)'[35](index=35&type=chunk)[41](index=41&type=chunk) - Highlights of main business operations: - **Technological Innovation**: The first phase of the '6 billion units/year Health Protective (New Type Gloves) Project' was completed and put into operation, enriching product categories - **Brand Marketing**: Engaged professional consultants to launch a domestic brand marketing strategy, with e-commerce revenue growing by nearly **10%** year-on-year, and sales network covering **30 provinces and cities** nationwide - **International Market**: Innovated trade methods, conducted multi-product portfolio sales, and increased customer stickiness[36](index=36&type=chunk)[37](index=37&type=chunk)[38](index=38&type=chunk) - The company actively promoted a major asset restructuring with cardiac stent manufacturer Biosensors International, aiming to acquire globally leading technology and sales networks for industrial upgrading[43](index=43&type=chunk) 2017 Operating Data | Indicator | Value | | :--- | :--- | | **Health Protective Glove Production Volume** | 14.104 billion units | | **Health Protective Glove Sales Volume** | 14.619 billion units | | **Operating Revenue** | 1.576 billion yuan | | **Total Profit** | 254 million yuan | | **Net Profit Attributable to Parent Company** | 201 million yuan | [Main Business Analysis](index=14&type=section&id=II.%20Main%20Business%20Analysis) In 2017, health protective glove revenue reached 1.521 billion yuan, up 18.99%, with gross margin increasing by 4.66 percentage points to 31.95%, driven by price increases and cost control 2017 Operating Revenue Composition | Category | Amount (yuan) | Proportion of Operating Revenue | Year-on-Year Change | | :--- | :--- | :--- | :--- | | **By Industry** | | | | | Health Protective Gloves | 1,520,594,486.12 | 96.49% | 18.99% | | **By Region** | | | | | Domestic | 168,169,249.43 | 10.67% | 65.10% | | Overseas | 1,407,776,060.00 | 89.33% | 18.61% | Main Business Gross Margin Analysis | Category | Operating Revenue | Operating Cost | Gross Margin | Gross Margin Year-on-Year Change | | :--- | :--- | :--- | :--- | :--- | | **Health Protective Gloves** | 1,520,594,486.12 | 1,034,823,849.28 | 31.95% | 4.66% | 2017 Period Expenses (Unit: yuan) | Expense Item | 2017 | 2016 | Year-on-Year Change | Explanation for Significant Change | | :--- | :--- | :--- | :--- | :--- | | **Selling Expenses** | 61,147,704.56 | 50,477,626.25 | 21.14% | Increased brand marketing expenses | | **Administrative Expenses** | 131,019,819.20 | 101,436,910.20 | 29.16% | Increased expenses for new M&A projects | | **Financial Expenses** | 23,175,578.72 | -21,139,310.28 | 209.63% | Exchange gains/losses due to RMB-USD exchange rate fluctuations | 2017 R&D Investment | Indicator | 2017 | 2016 | Change Percentage | | :--- | :--- | :--- | :--- | | **R&D Investment Amount (yuan)** | 49,724,366.03 | 39,593,396.67 | 25.59% | | **R&D Investment as % of Operating Revenue** | 3.16% | 3.07% | 0.09% | Key Cash Flow Statement Items for 2017 (Unit: yuan) | Item | Current Period Amount | Prior Period Amount | Year-on-Year Change | | :--- | :--- | :--- | :--- | | **Net Cash Flow from Operating Activities** | 227,567,253.64 | 163,926,593.84 | 38.82% | | **Net Cash Flow from Investing Activities** | -230,449,818.09 | -58,896,266.20 | -291.28% | | **Net Cash Flow from Financing Activities** | -39,314,103.40 | -101,490,850.90 | 61.26% | | **Net Increase in Cash and Cash Equivalents** | -51,029,075.07 | 13,773,561.72 | -470.49% | [Outlook for Company's Future Development](index=25&type=section&id=IX.%20Outlook%20for%20Company%27s%20Future%20Development) The company plans to pursue a dual-business strategy of 'health protection + medical health', expanding existing glove products while entering high-value medical consumables through the Biosensors International acquisition - The company has formulated a dual-segment development strategy emphasizing both 'health protection business' and 'medical health business', aiming for a complementary and risk-hedging business layout of low-value and high-value consumables[87](index=87&type=chunk) - **Health Protection Business Strategy**: - Leveraging glove products as a cornerstone, expanding product lines through self-construction to offer a 'one-stop' product portfolio - Actively expanding domestic sales channels and developing the individual consumer (to C) segment - Vigorously promoting the 'Lanfei' brand to enhance brand premium[88](index=88&type=chunk) - **Medical Health Business Strategy**: - Entering the high-value cardiology consumables sector by acquiring Biosensors International - Expanding product lines around existing departmental platforms through independent R&D and M&A incubation - Prudently researching and primarily entering other strategically valuable departmental areas such as surgery, orthopedics, and IVD through M&A[89](index=89&type=chunk) - **2018 Operating Plan**: - **Operating Targets**: Health protective glove production and sales volume to reach **17 billion units**, operating revenue of **1.7 billion yuan** - **Strategic Development**: Continue to advance major asset restructuring and optimize industrial layout - **Production Operations**: Increase investment in automation, intelligence, and informatization construction - **Brand Building**: Fully implement the domestic brand marketing strategy[92](index=92&type=chunk)[93](index=93&type=chunk) - Key risks faced by the company include: rising raw material prices, uncertainties in new project commissioning, increased environmental pressure, exchange rate fluctuations, and operational management and integration risks in new business areas and major asset restructuring[98](index=98&type=chunk)[99](index=99&type=chunk)[100](index=100&type=chunk) [Significant Matters](index=30&type=section&id=Section%205%20Significant%20Matters) This section details the company's profit distribution, equity incentives, related party transactions, and other significant events [Profit Distribution and Equity Incentives](index=30&type=section&id=Profit%20Distribution%20and%20Equity%20Incentives) The company proposed a 2017 cash dividend of 2.00 yuan per 10 shares, representing a 49.22% payout ratio, and completed the second unlocking period of its restricted stock incentive plan Cash Dividends for Ordinary Shares in the Last Three Years (Unit: yuan) | Dividend Year | Cash Dividend Amount (Tax Inclusive) | Net Profit Attributable to Parent Company | Ratio to Net Profit Attributable to Parent Company | | :--- | :--- | :--- | :--- | | **2017** | 98,871,000.00 | 200,864,341.90 | 49.22% | | **2016** | 98,871,000.00 | 181,069,380.03 | 54.60% | | **2015** | 98,880,000.00 | 170,211,819.24 | 58.09% | - In February 2017, the conditions for the second unlocking period of the company's restricted stock incentive plan were met, with **58 incentive recipients** unlocking a total of **3.585 million restricted shares**[128](index=128&type=chunk) [Significant Related Party Transactions](index=36&type=section&id=Significant%20Related%20Party%20Transactions) Significant related party transactions in 2017 primarily involved the procurement of raw materials like plasticizers and PVC from affiliated companies, totaling approximately 250 million yuan Key Related Party Procurement in 2017 (Unit: ten thousand yuan) | Related Party | Related Transaction Content | Related Transaction Amount | Proportion of Similar Transactions | | :--- | :--- | :--- | :--- | | **Shandong Lanfei Chemical Co., Ltd.** | Plasticizer | 4,766.65 | 6.44% | | **Shandong Langhui Petrochemical Co., Ltd.** | Plasticizer | 10,047.18 | 13.58% | | **Shandong Langhui Petrochemical Co., Ltd.** | PVC | 10,136.48 | 13.70% | - Among the top five suppliers, related party procurement accounted for **27.80%** of the total annual procurement[55](index=55&type=chunk) [Significant Contracts and Their Performance](index=40&type=section&id=Significant%20Contracts%20and%20Their%20Performance) The company provided guarantees for affiliated party Langhui Petrochemical (13.3409 million yuan) and its wholly-owned subsidiary Lanfei New Materials (50 million yuan), and invested 215 million yuan in bank wealth management products, all matured - The company provided guarantees for related party Langhui Petrochemical, with an actual guarantee balance of **13.3409 million yuan** at the end of the reporting period[144](index=144&type=chunk)[145](index=145&type=chunk) - The company provided guarantees for its wholly-owned subsidiary Lanfei New Materials, with an actual guarantee balance of **50 million yuan** at the end of the reporting period[144](index=144&type=chunk)[145](index=145&type=chunk) - During the reporting period, the company used its own funds to purchase bank wealth management products, with a cumulative amount of **215 million yuan** and zero outstanding balance at period-end[148](index=148&type=chunk) [Other Significant Matters](index=47&type=section&id=Other%20Significant%20Matters) Key events include the company and its subsidiary obtaining high-tech enterprise certificates, a 7.08% share transfer by the controlling shareholder, board/supervisory board/senior management re-election, and the initiation of a major asset restructuring to acquire Biosensors International - The company initiated a major asset restructuring, proposing to acquire **93.37%** of cardiac stent manufacturer Biosensors International's shares through a share issuance and cash payment (total consideration of **5.895 billion yuan**), with the application submitted to the CSRC in January 2018[173](index=173&type=chunk)[174](index=174&type=chunk) - Controlling shareholder Lanfei Group transferred **35 million shares**, representing **7.08%** of the total share capital, to Zhuhai Juqing Qinfeng Lusong Equity Investment Center (Limited Partnership) via agreement in March 2017[169](index=169&type=chunk) - The first phase (2 billion units/year) of the company's '6 billion units/year Health Protective (New Type Gloves) Project' was completed and put into operation in July 2017[170](index=170&type=chunk) [Share Changes and Shareholder Information](index=54&type=section&id=Section%206%20Share%20Changes%20and%20Shareholder%20Information) This section details changes in the company's share capital and the composition of its shareholders [Share Changes and Shareholder Structure](index=54&type=section&id=Share%20Changes%20and%20Shareholder%20Structure) The company's total share capital remained at 494.355 million shares, with changes in restricted shares due to equity incentive unlocking, and the top two shareholders holding 43.90% as of year-end 2017 Share Change Status (Unit: shares) | Category | Before This Change | Increase/Decrease in This Change | After This Change | | :--- | :--- | :--- | :--- | | **I. Restricted Shares** | 12,839,286 | -2,571,250 | 10,268,036 | | **II. Unrestricted Shares** | 481,515,714 | +2,571,250 | 484,086,964 | | **III. Total Shares** | 494,355,000 | 0 | 494,355,000 | - Share changes were primarily due to the unlocking of the second period of the equity incentive plan, with **3.585 million shares** becoming unrestricted, and some executive lock-up shares reclassified as restricted[180](index=180&type=chunk)[181](index=181&type=chunk) Top Ten Shareholders' Holdings at End of Reporting Period | Shareholder Name | Shareholder Nature | Holding Percentage | Number of Shares Held | | :--- | :--- | :--- | :--- | | **Zibo Lanfei Investment Co., Ltd.** | Domestic Non-State-Owned Legal Person | 29.72% | 146,900,000 | | **Lanfei Group Co., Ltd.** | Domestic Non-State-Owned Legal Person | 14.18% | 70,100,000 | | **Zhongxuan Investment Co., Ltd.** | Overseas Legal Person | 12.18% | 60,188,000 | | **Zhuhai Juqing Qinfeng Lusong Equity Investment Center** | Domestic Non-State-Owned Legal Person | 7.08% | 35,000,000 | | **Shanghai Kangcheng Investment Center** | Domestic Non-State-Owned Legal Person | 3.91% | 19,334,127 | - The company's controlling shareholders are Lanfei Group Co., Ltd. and its concerted party Zibo Lanfei Investment Co., Ltd., with Mr. Li Zhenping as the actual controller[189](index=189&type=chunk)[190](index=190&type=chunk)[191](index=191&type=chunk) [Preferred Shares Information](index=60&type=section&id=Section%207%20Preferred%20Shares%20Information) This section confirms the absence of preferred shares during the reporting period [Preferred Shares Status](index=60&type=section&id=Preferred%20Shares%20Status) The company had no preferred shares during the reporting period - The company had no preferred shares during the reporting period[195](index=195&type=chunk) [Directors, Supervisors, Senior Management, and Employees](index=61&type=section&id=Section%208%20Directors,%20Supervisors,%20Senior%20Management,%20and%20Employees) This section provides information on the company's board, supervisory board, senior management, and employee structure [Directors, Supervisors, Senior Management, and Employee Information](index=61&type=section&id=Directors,%20Supervisors,%20Senior%20Management,%20and%20Employee%20Information) The company completed board and supervisory board re-elections, with a diverse and experienced team, and had 3,294 employees at year-end 2017, primarily in production, supported by performance-linked compensation and training - During the reporting period, the company completed the re-election of its board of directors and supervisory board, with independent directors Shen Ziyu and Zhao Yao, supervisory board chairman Xu Xinrong, and marketing director Ho Weng Fatt departing due to term expiration[199](index=199&type=chunk) 2017 Compensation for Directors, Supervisors, and Senior Management (Unit: ten thousand yuan) | Name | Position | Total Pre-tax Compensation from Company | Received Compensation from Company's Related Parties | | :--- | :--- | :--- | :--- | | **Liu Wenjing** | Chairman | 174 | No | | **Li Zhenping** | Director | 174 | Yes | | **Sun Chuanzhi** | Director, General Manager, CFO | 73.4 | No | | **Total** | -- | **607.31** | -- | Employee Composition | Category | Number of People | Proportion | | :--- | :--- | :--- | | **Total Number of Employees** | 3,294 | 100% | | **Professional Structure** | | | | Production Personnel | 2,023 | 61.4% | | Technical Personnel | 961 | 29.2% | | Administrative Personnel | 221 | 6.7% | | Sales Personnel | 72 | 2.2% | | Financial Personnel | 17 | 0.5% | | **Education Level** | | | | College Degree and Above | 1,179 | 35.8% | | Secondary Vocational School and Below High School | 2,115 | 64.2% | [Corporate Governance](index=70&type=section&id=Section%209%20Corporate%20Governance) This section describes the company's corporate governance structure and internal control system [Corporate Governance Status](index=70&type=section&id=Corporate%20Governance%20Status) The company's corporate governance aligns with regulatory requirements, maintaining independence from its controlling shareholder, with effective board committees and a sound internal control system - The company's actual corporate governance status complies with the normative documents on listed company governance issued by the China Securities Regulatory Commission, with no significant discrepancies[225](index=225&type=chunk)[235](index=235&type=chunk) - The company is fully independent from its controlling shareholder in terms of business, personnel, assets, organization, and finance, possessing a complete business system and autonomous operating capabilities[236](index=236&type=chunk)[237](index=237&type=chunk) - The four special committees under the Board of Directors—Audit, Strategy, Remuneration and Appraisal, and Nomination—diligently performed their duties during the reporting period, holding multiple meetings to deliberate relevant proposals[244](index=244&type=chunk)[245](index=245&type=chunk)[246](index=246&type=chunk) - The company's Board of Directors believes that its internal controls are effective, with no material weaknesses in financial or non-financial reporting, and the accounting firm issued a standard unqualified opinion on the internal control attestation report[250](index=250&type=chunk)[252](index=252&type=chunk)[253](index=253&type=chunk) [Corporate Bonds Information](index=78&type=section&id=Section%2010%20Corporate%20Bonds%20Information) This section confirms the absence of outstanding corporate bonds [Corporate Bonds Status](index=78&type=section&id=Corporate%20Bonds%20Status) The company had no publicly issued and listed corporate bonds that were outstanding or fully unpaid as of the report approval date - The company had no publicly issued and listed corporate bonds that were outstanding or fully unpaid as of the annual report approval date[256](index=256&type=chunk) [Financial Report](index=79&type=section&id=Section%2011%20Financial%20Report) This section presents the audited financial statements, including the balance sheet, income statement, and cash flow statement [Audit Report](index=79&type=section&id=Audit%20Report) Daxin Certified Public Accountants (Special General Partnership) issued a standard unqualified audit opinion on the company's 2017 financial statements, with related party transactions identified as a key audit matter - Daxin Certified Public Accountants issued a standard unqualified audit opinion[258](index=258&type=chunk) - A key audit matter was related party transactions; due to the significant amount and proportion of raw material purchases from related parties (**34.70%** of total raw material purchases), auditors focused on the authenticity and fairness of transaction prices[260](index=260&type=chunk) [Financial Statements](index=81&type=section&id=Financial%20Statements) As of year-end 2017, total assets were 1.837 billion yuan (up 15.75%), net profit attributable to parent company was 201 million yuan (up 10.93%), and net cash flow from operating activities was 228 million yuan (up 38.82%) Key Consolidated Balance Sheet Items (Unit: yuan) | Item | Period-end Balance | Beginning Balance | | :--- | :--- | :--- | | **Total Current Assets** | 765,233,441.58 | 839,993,709.09 | | **Total Non-current Assets** | 1,071,803,683.04 | 747,021,177.21 | | **Total Assets** | 1,837,037,124.62 | 1,587,014,886.30 | | **Total Current Liabilities** | 391,229,028.33 | 273,986,628.64 | | **Total Liabilities** | 408,728,551.52 | 286,984,433.84 | | **Total Equity Attributable to Parent Company Owners** | 1,426,156,427.31 | 1,298,896,635.77 | | **Total Owners' Equity** | 1,428,308,573.10 | 1,300,030,452.46 | Key Consolidated Income Statement Items (Unit: yuan) | Item | Current Period Amount | Prior Period Amount | | :--- | :--- | :--- | | **I. Total Operating Revenue** | 1,575,945,309.43 | 1,288,770,719.80 | | **II. Total Operating Costs** | 1,324,591,830.01 | 1,090,715,681.52 | | **III. Operating Profit** | 257,671,741.32 | 216,948,736.75 | | **IV. Total Profit** | 253,623,792.85 | 220,071,341.20 | | **V. Net Profit** | 201,974,096.53 | 180,320,697.54 | | **Net Profit Attributable to Parent Company Owners** | 200,864,341.90 | 181,069,380.03 | Key Consolidated Cash Flow Statement Items (Unit: yuan) | Item | Current Period Amount | Prior Period Amount | | :--- | :--- | :--- | | **Net Cash Flow from Operating Activities** | 227,567,253.64 | 163,926,593.84 | | **Net Cash Flow from Investing Activities** | -230,449,818.09 | -58,896,266.20 | | **Net Cash Flow from Financing Activities** | -39,314,103.40 | -101,490,850.90 | | **Net Increase in Cash and Cash Equivalents** | -51,029,075.07 | 13,773,561.72 | [Reference Documents Catalog](index=169&type=section&id=Section%2012%20Reference%20Documents%20Catalog) This section lists the documents available for reference, including the original annual report, financial statements, and audit report [Reference Documents](index=169&type=section&id=Reference%20Documents) Reference documents, including the original annual reports, financial statements, and audit reports, are stored at the company's securities management department - Reference documents, including original annual reports, financial statements, and audit reports, are stored at the company's securities management department[610](index=610&type=chunk)

蓝帆医疗股份有限公司 2017 年第三季度报告全文 蓝帆医疗股份有限公司 BLUE SAIL MEDICAL CO.,LTD. （山东省淄博市齐鲁化学工业区清田路 21 号） 二〇一七年第三季度报告 （未经审计） 股票代码：002382 二〇一七年十月 1 蓝帆医疗股份有限公司 2017 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人刘文静、主管会计工作负责人孙传志及会计机构负责人(会计主 管人员)白雪莲声明：保证季度报告中财务报表的真实、准确、完整。 2 蓝帆医疗股份有限公司 2017 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,782,309,956.68 | 1, ...

蓝帆医疗股份有限公司 2017 年半年度报告全文 蓝帆医疗股份有限公司 BLUE SAIL MEDICAL CO.,LTD. （山东省淄博市齐鲁化学工业区清田路 21 号） 二〇一七年半年度报告 （未经审计） 股票代码：002382 二〇一七年八月 1 蓝帆医疗股份有限公司 2017 年半年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人刘文静、主管会计工作负责人孙传志及会计机构负责人(会计主 管人员)白雪莲声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司已在本半年度报告中详细描述了公司面临的风险，敬请投资者予以关 注，详见本半年度报告"经营情况讨论与分析 "等章节中关于公司面临风险的描 述。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | --- | | 第一节 重要提示、目录和释义 | 2 | | --- | --- | | 第二节 公司简介和主要财务指标 | 5 | ...

蓝帆医疗股份有限公司 2017 年第一季度报告正文 证券代码：002382 证券简称：蓝帆医疗 公告编号：2017-024 蓝帆医疗股份有限公司 二〇一七年第一季度报告正文 二〇一七年四月 1 蓝帆医疗股份有限公司 2017 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人刘文静、主管会计工作负责人孙传志及会计机构负责人(会计主 管人员)白雪莲声明：保证季度报告中财务报表的真实、准确、完整。 2 蓝帆医疗股份有限公司 2017 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 402,521,260.12 | 325,697,228.46 | 23.59% | | 归属于 ...

蓝帆医疗股份有限公司 2016 年年度报告全文 蓝帆医疗股份有限公司 BLUE SAIL MEDICAL CO.,LTD. （山东省淄博市齐鲁化学工业区清田路 21 号） 二〇一六年年度报告 股票代码：002382 二〇一七年二月 1 蓝帆医疗股份有限公司 2016 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人刘文静、主管会计工作负责人孙传志及会计机构负责人(会计主 管人员)白雪莲声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司已在本年度报告中详细描述了公司面临的风险，敬请投资者予以关注， 详见本年度报告"经营情况讨论与分析"等章节中关于公司面临风险的描述。 公司经本次董事会审议通过的利润分配预案为：以 494,355,000 为基数，向 全体股东每 10 股派发现金红利 2.00 元（含税），送红股 0 股（含税），不以公积 金转增股本。 2 | 目录 | | --- | | 第一节 重要提示、 ...

蓝帆医疗股份有限公司 2016 年第三季度报告正文 证券代码：002382 证券简称：蓝帆医疗 公告编号：2016-055 蓝帆医疗股份有限公司 二〇一六年第三季度报告正文 二〇一六年十月 1 蓝帆医疗股份有限公司 2016 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人刘文静、主管会计工作负责人孙传志及会计机构负责人(会计主 管人员)白雪莲声明：保证季度报告中财务报表的真实、准确、完整。 2 蓝帆医疗股份有限公司 2016 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,527,647,837.15 | | 1,497,269,917 ...